Insufficient use of menopausal hormone therapy in Swedish women with early or premature menopause caused by bilateral oophorectomy: a register-based study.
early menopause
menopausal hormone therapy
oophorectomy
premature menopause
Journal
BJOG : an international journal of obstetrics and gynaecology
ISSN: 1471-0528
Titre abrégé: BJOG
Pays: England
ID NLM: 100935741
Informations de publication
Date de publication:
05 Sep 2023
05 Sep 2023
Historique:
revised:
14
08
2023
received:
05
06
2023
accepted:
19
08
2023
medline:
5
9
2023
pubmed:
5
9
2023
entrez:
5
9
2023
Statut:
aheadofprint
Résumé
To investigate the use of menopausal hormone therapy (MHT) in premenopausal women after bilateral oophorectomy. Retrospective register-based cohort study. Sweden. Swedish women aged 35-44 years without malignancy who underwent bilateral oophorectomy in 2005-2020 were identified using The Swedish National Quality Register of Gynaecological Surgery (GynOp). Data from GynOp were cross-linked with data on dispensed drugs extracted from the Swedish Prescribed Drug Register. Proportion of women dispensed MHT at least once within 1 year after surgery. Repeated treatment episodes were defined, and the proportion of 'person time' covered by dispensations was analysed. In total, 1231 of all women (n = 1706) were dispensed MHT at some point after surgery, with 1177 women dispensed MHT within 1 year. This proportion increased from 64% in 2005 to 84% in 2019 (p < 0.001). In the total population, 4537 'treatment years' transpired, corresponding to 43% of the mean time covered. In women dispensed MHT within 1 year, the proportion of time covered was 63%. Only 69% of all women without malignancy of any kind who underwent bilateral oophorectomy were dispensed MHT within 1 year after surgery, and the duration of treatment was limited. It is important to study further the reasons behind the low dispensation rate in this group to increase adherence to current treatment guidelines, improve quality of life, and avoid increased morbidity and mortality.
Identifiants
pubmed: 37667667
doi: 10.1111/1471-0528.17647
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Forskningsrådet i Sydöstra Sverige
Organisme : the NEPI foundation
Informations de copyright
© 2023 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.
Références
Gold EB, Bromberger J, Crawford S, Samuels S, Greendale GA, Harlow SD, et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol. 2001;153(9):865-874.
Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol. 1986;67(4):604-606.
Luborsky JL, Meyer P, Sowers MF, Gold EB, Santoro N. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod. 2003;18(1):199-206.
Lagergren K, Hammar M, Nedstrand E, Bladh M, Sydsjö G. The prevalence of primary ovarian insufficiency in Sweden; a national register study. BMC Womens Health. 2018;18(1):175.
Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause. 2006;13(2):265-279.
Rivera CM, Grossardt BR, Rhodes DJ, Brown RD Jr, Roger VL, Melton LJ 3rd, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause. 2009;16(1):15-23.
Lokkegaard E, Jovanovic Z, Heitmann BL, Keiding N, Ottesen B, Pedersen AT. The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy. Maturitas. 2006;53(2):226-233.
Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol. 2009;113(5):1027-1037.
Muka T, Oliver-Williams C, Kunutsor S, Laven JS, Fauser BC, Chowdhury R, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol. 2016;1(7):767-776.
Zhu D, Chung HF, Dobson AJ, Pandeya N, Giles GG, Bruinsma F, et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health. 2019;4(11):e553-e564.
Yoshida T, Takahashi K, Yamatani H, Takata K, Kurachi H. Impact of surgical menopause on lipid and bone metabolism. Climacteric. 2011;14(4):445-452.
Svejme O, Ahlborg HG, Nilsson J, Karlsson MK. Early menopause and risk of osteoporosis, fracture and mortality: a 34-year prospective observational study in 390 women. BJOG. 2012;119(7):810-816.
Bove R, Secor E, Chibnik LB, Barnes LL, Schneider JA, Bennett DA, et al. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology. 2014;82(3):222-229.
Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007;69(11):1074-1083.
Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ 3rd. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006;7(10):821-828.
Hendrix SL. Bilateral oophorectomy and premature menopause. Am J Med. 2005;118(Suppl 12B):131-135.
Gallicchio L, Whiteman MK, Tomic D, Miller KP, Langenberg P, Flaws JA. Type of menopause, patterns of hormone therapy use, and hot flashes. Fertil Steril. 2006;85(5):1432-1440.
Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. Maturitas. 2010;65(2):161-166.
Popat VB, Calis KA, Kalantaridou SN, Vanderhoof VH, Koziol D, Troendle JF, et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J Clin Endocrinol Metab. 2014;99(9):3418-3426.
Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril. 2016;106(7):1588-1599.
Neves ECM, Birkhauser M, Samsioe G, Lambrinoudaki I, Palacios S, Borrego RS, et al. EMAS position statement: the ten point guide to the integral management of menopausal health. Maturitas. 2015;81(1):88-92.
The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2017;24(7):728-753.
Swedish Society of Obstetrics and Gynecology. SFOG-Råd för menopausal hormonbehandling 2019, uppdaterad version 2021. 2021. Available from: https://www.sfog.se/media/337273/mht-sfog-raad-210121.pdf
Jang JH, Arora N, Kwon JS, Hanley GE. Hormone therapy use after premature surgical menopause based on prescription records: a population-based study. J Obstet Gynaecol Can. 2020;42(12):1511-1517.
Chubaty A, Shandro MT, Schuurmans N, Yuksel N. Practice patterns with hormone therapy after surgical menopause. Maturitas. 2011;69(1):69-73.
Lindh-Astrand L, Hoffmann M, Jarvstrat L, Fredriksson M, Hammar M, Spetz Holm AC. Hormone therapy might be underutilized in women with early menopause. Hum Reprod. 2015;30(4):848-852.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280(7):605-613.
Read MD, Edey KA, Hapeshi J, Foy C. Compliance with estrogen hormone replacement therapy after oophorectomy: a prospective study. Menopause Int. 2010;16(2):60-64.
Kalu EO, Bolger B. Commencement and maintenance compliance of patients on hormone replacement therapy (HRT) following bilateral oophorectomy. Journal of Obstetrics and Gynaecology. 2001;21(2):173-174.
The Swedish National Quality Register of Gynecological Surgery. GynOp. 2023. Available from: https://statistik.incanet.se/gynop/
Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish prescribed drug register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726-735.
Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659-667.
World Health Organization. Structure and Principles. 2023. [updated 2022 Nov 10; cited 2023 Feb 12]. Available from: https://www.whocc.no/atc/structure_and_principles/
The Riksdag. The Act concerning the Ethical Review of Research Involving Humans (SFS 2003:460) Stockholm: The Riksdag. Available from: https://www.riksdagen.se/sv/dokument-lagar/dokument/svensk-forfattningssamling/lag-2003460-om-etikprovning-av-forskning-som_sfs-2003-460
Sveriges Riksdag. Offentlighets- och sekretesslag (2009:400). 2009. Available from: https://www.riksdagen.se/sv/dokument-lagar/dokument/svensk-forfattningssamling/offentlighets--och-sekretesslag-2009400_sfs-2009-400
Karlsson P, Nakitanda AO, Löfling L, Cesta CE. Patterns of prescription dispensation and over-the-counter medication sales in Sweden during the COVID-19 pandemic. PLoS One. 2021;16(8):e0253944.
von Kartaschew ÅE, Dahm-Kähler P, Rodriguez-Wallberg KA, Holmberg E, Rådestad AF. Hormone replacement in premenopausal women treated with bilateral oophorectomy for ovarian cancer - a nationwide population-based study. Gynecol Oncol. 2022;167(3):476-482.
Björn I, Bixo M, Nöjd KS, Nyberg S, Bäckström T. Negative mood changes during hormone replacement therapy: a comparison between two progestogens. Am J Obstet Gynecol. 2000;183(6):1419-1426.
Björn I, Bäcksröm T. Drug related negative side-effects is a common reason for poor compliance in hormone replacement therapy. Maturitas. 1999;32(2):77-86.
Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291(1):47-53.
Hoffmann M, Hammar M, Kjellgren KI, Lindh-Astrand L, Brynhildsen J. Changes in women's attitudes towards and use of hormone therapy after HERS and WHI. Maturitas. 2005;52(1):11-17.
Lindh-Astrand L, Hoffmann M, Hammar M, Spetz Holm AC. Hot flushes, hormone therapy and alternative treatments: 30 years of experience from Sweden. Climacteric. 2015;18(1):53-62.
Buist DS, Newton KM, Miglioretti DL, Beverly K, Connelly MT, Andrade S, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol. 2004;104(5 Pt 1):1042-1050.
Beral V. Breast cancer and hormone-replacement therapy in the million women study. Lancet. 2003;362(9382):419-427.
Siyam T, Ross S, Shandro T, Hagen S, Battochio L, Yuksel N. Perspectives and decision-making about menopausal therapies in women who had bilateral oophorectomy. Menopause. 2018;25(7):795-802.